Strategic corporate decision:

Bayer Board of Management plans to focus entirely on Life Science businesses

Leverkusen, September 18, 2014

The Board of Management of Bayer AG plans to focus the Bayer Group entirely on the Life Science businesses – HealthCare and CropScience – and float MaterialScience on the stock market as a separate company. In this way Bayer would position itself as a world-leading company in the field of human, animal and plant health. The plans remain subject to the approval of the Supervisory Board.

The Board of Management decided this on September 2, 2014. The Supervisory Board of Bayer AG will discuss the plans at its meeting today, Thursday. It is planned to release further information when the Supervisory Board has reached its decision.

Forward-Looking Statements
This Ad-hoc Statement may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Constance Spitzer (+49-214-30-33021)
Dr. Olaf Weber (+49-214-30-33567)